【摘要】：目的觀察坦索羅辛膠囊聯(lián)合益氣活血方治療經(jīng)皮腎鏡超聲彈道碎石術(shù)后腎損傷的臨床療效及安全性。方法將52例經(jīng)皮腎鏡超聲彈道碎石術(shù)后腎損傷患者隨機(jī)分為對(duì)照組26例與試驗(yàn)組26例。對(duì)照組予以口服鹽酸坦索羅辛緩釋膠囊每次0.4 mg,qd;試驗(yàn)組在對(duì)照組治療的基礎(chǔ)上,予以口服益氣活血方每次100 m L,早晚各一次。2組患者均治療28 d。比較2組患者的臨床療效、血清胱抑素C(Cys-C)、腎損傷分子1(Kim~(~(-1)))、24 h尿蛋白定量(24 h Up)、血尿酸(UA)、血清肌酸酐(SCr)、尿素氮(BUN)水平,以及藥物不良反應(yīng)的發(fā)生情況。結(jié)果治療后,試驗(yàn)組和對(duì)照組的總有效率分別為84.62%(22/26例)和57.69%(15/26例),差異有統(tǒng)計(jì)學(xué)意義(P0.05)。治療后,試驗(yàn)組和對(duì)照組的Cys-C分別為(1.65±0.27),(2.01±0.29)mg·L~(~(-1));Kim~(~(-1))分別為(31.38±3.76),(39.02±4.88)pg·m L~(~(-1));24 h Up分別為(0.52±0.07),(0.81±0.10)g·d~(~(-1));UA分別為(428.07±50.39),(468.93±52.26)μmol·L~(~(-1));SCr分別為(329.02±40.11),(398.02±45.44)μmol·L~(~(-1));BUN分別為(14.09±1.78),(18.00±2.44)mmol·L~(~(-1)),差異均有統(tǒng)計(jì)學(xué)意義(均P0.05)。試驗(yàn)組的藥物不良反應(yīng)主要有頭痛、腹瀉和手足皮膚反應(yīng),對(duì)照組的藥物不良反應(yīng)主要有頭痛、高血壓和腹瀉。試驗(yàn)組和對(duì)照組的藥物不良反應(yīng)發(fā)生率分別為11.54%和15.38%,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論坦索羅辛膠囊聯(lián)合益氣活血方治療經(jīng)皮腎鏡超聲彈道碎石術(shù)后腎損傷的臨床療效顯著,且不增加藥物不良反應(yīng)的發(fā)生率。
[Abstract]:Objective to observe the clinical efficacy and safety of tansoloxin capsule combined with Yiqi Huoxue recipe in the treatment of renal injury after percutaneous nephroscopic ultrasound ballistic lithotripsy. Methods 52 patients with renal injury after percutaneous nephroscopic ultrasound lithotripsy were randomly divided into control group (n = 26) and experimental group (n = 26). The control group was administered orally with tansoloxine hydrochloride sustained release capsule each time. On the basis of the treatment in the control group, 100ml of Yiqi Huoxue prescription was given orally, once in the morning and evening. The patients in both groups were treated for 28 days. The clinical efficacy, serum cystatin C (Cys-C), renal injury molecule 1 (Kim~ (-1), 24 h urinary protein quantification (24 h Up), serum creatinine (SCr),) were compared between the two groups. Urea nitrogen (BUN) levels and adverse drug reactions. Results after treatment, the total effective rates of the experimental group and the control group were 84.62% (22 / 26 cases) and 57.69% (15 / 26 cases), respectively. The difference was statistically significant (P0.05). After treatment, the Cys-C of the trial group and the control group were (1.65 鹵0.27), (2.01 鹵0.29) mg L ~ (-1);, respectively. Kim~ (-1) were (31.38 鹵3.76), () 39.02 鹵4.88) pg m L-1); 24 h Up (0.52 鹵0.07), (0.81 鹵0.10) g d-1);, respectively. UA was (428.07 鹵50.39), (468.93 鹵52.26) 渭 mol L ~ (-1); SCr (329.02 鹵40.11), (398.02 鹵45.44) 渭 mol L ~ (-1);, respectively. BUN was (14.09 鹵1.78), (18.00 鹵2.44) mmol L ~ (-1), (P0.05). The main adverse drug reactions in the trial group were headache, diarrhea and skin reaction of the hands and feet, and the adverse drug reactions in the control group were headache, hypertension and diarrhea. The incidence of adverse drug reactions in experimental group and control group were 11.54% and 15.38%, respectively, with no significant difference (P0.05). Conclusion the clinical effect of tansoloxin capsule combined with Yiqi Huoxue recipe in treating renal injury after percutaneous nephroscopic ultrasound ballistic lithotripsy is significant and the incidence of adverse drug reaction is not increased.
【作者單位】： 海南省農(nóng)墾那大醫(yī)院泌尿外科;
【基金】：國(guó)家醫(yī)學(xué)教育發(fā)展中心醫(yī)學(xué)研究課題基金資助項(xiàng)目(2010-37-03-004)
【分類(lèi)號(hào)】：R699
，

本文編號(hào)：2349686